Biocon Limited Q3 FY23 Investor Presentation February 2023

Loading viewer...

investor_presentation

Format: PDF investor_presentation

Biocon Limited presents its Q3 FY23 financial and operational results as a global biopharmaceutical leader. The company operates with revenue of ₹8,397 Cr (~$1.1 bn) and serves over 120 countries with innovative, affordable therapies across 7 manufacturing facilities.

Browse all investor_presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Biocon Limited

View all →

Biocon Limited Q2 FY23 Investor Presentation 2022

investor_presentation

32 Pages

Biocon Limited Q3 FY2022 Investor Presentation January 2022

investor_presentation

Similar investor_presentations from other companies

Browse all →

Helios Technologies Investor Presentation — November 2019

investor_presentation

24 Pages

Helios Technologies

Wyndham Hotels & Resorts Investor Presentation — October 2020

investor_presentation